March 28 (Reuters) - Palatin Technologies Inc PTN.A:
PALATIN ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 ULCERATIVE COLITIS (UC) STUDY OF ORAL MELANOCORTIN-1 RECEPTOR AGONIST PL8177
PALATIN: CLINICAL REMISSION ACHIEVED IN 33% OF PL8177-TREATED PATIENTS VERSUS 0% ON PLACEBO AFTER EIGHT WEEKS OF TREATMENT
PALATIN TECHNOLOGIES INC: SAFETY AND TOLERABILITY: EXCELLENT, WITH NO ADVERSE EVENTS
PALATIN: STATISTICALLY SIGNIFICANT CLINICAL RESPONSE SEEN IN 78% OF PL8177-TREATED PATIENTS VERSUS 33% ON PLACEBO AFTER 8 WEEKS OF TREATMENT
Source text: ID:nPn4BYDMga
Further company coverage: PTN.A
((Reuters.Briefs@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。